Edelweiss Evrard

Pfizer (United States) — United States

Computer Science · Physical Sciences

12h-index496citations15works7.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(3), Chemical Synthesis and Analysis(3), Receptor Mechanisms and Signaling(3), Tryptophan and brain disorders(3), Synthesis and Catalytic Reactions(3)

Publications15 total

Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948
Journal of Medicinal Chemistry·2024· 10 cited
Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer’s Disease
Journal of Medicinal Chemistry·2024· 5 citedOpen Access
Scalable, Telescoped Hydrogenolysis–Enzymatic Decarboxylation Process for the Asymmetric Synthesis of (<i>R</i>)-α-Heteroaryl Propionic Acids
Organic Process Research & Development·2020· 13 cited
Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoE
Cell chemical biology·2020· 26 cited
Introduction of a Crystalline, Shelf-Stable Reagent for the Synthesis of Sulfur(VI) Fluorides
Organic Letters·2018· 135 cited
Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy
MedChemComm·2016· 17 citedOpen Access
CCDC 1452774: Experimental Crystal Structure Determination
The Cambridge Structural Database·2016Open Access
Discovery of indole-derived pyridopyrazine-1,6-dione γ-secretase modulators that target presenilin
Bioorganic & Medicinal Chemistry Letters·2014· 19 citedOpen Access
PF-04859989 as a template for structure-based drug design: Identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency
Bioorganic & Medicinal Chemistry Letters·2013· 31 citedOpen Access
Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions
ACS Medicinal Chemistry Letters·2012· 23 citedOpen Access
Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics
MedChemComm·2012· 20 cited
Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia
ACS Medicinal Chemistry Letters·2012· 88 citedOpen Access
Synthesis of ortho-substituted nitroaromatics via improved Negishi coupling conditions
Tetrahedron Letters·2011· 15 cited
A General Strategy for the Synthesis of Cyclic <i>N</i>-Aryl Hydroxamic Acids via Partial Nitro Group Reduction
The Journal of Organic Chemistry·2011· 21 cited
Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models
Journal of Medicinal Chemistry·2009· 73 citedOpen Access

Frequent Co-authors

Patrick R. Verhoest(11), Jamison B. Tuttle(7), John M. Humphrey(6), Christopher W. am Ende(6), Amy B. Dounay(6), Bruce M. Bechle(6), Todd W. Butler(5), Christopher J. Helal(5), Xinmin Gan(5), Somraj Ghosh(5), Laura A. McAllister(5), Vinod D. Parikh(5), Douglas S. Johnson(5), Martin Pettersson(5), Jayvardhan Pandit(4), Michelle A. Salafia(4), Laura E. Zawadzke(4), Longfei Xie(4), Gregory W. Kauffman(4), Antonia F. Stepan(4)